Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 9, 2025 • 1:41 PM ET

Date/Time Source News Release
07/02/2025 04:15 PM EDT GlobeNewswire Oragenics Completes Approximately $16.5 Million Offering
07/01/2025 08:31 AM EDT GlobeNewswire Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
06/10/2025 08:30 AM EDT GlobeNewswire Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
05/28/2025 07:00 AM EDT GlobeNewswire Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
05/13/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
05/12/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
04/23/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
04/09/2025 08:58 AM EDT GlobeNewswire Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
04/07/2025 04:30 PM EDT GlobeNewswire Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
03/27/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Page